Showing results (31-40 of 156) with videos related to
Sort By:
Pageof 16
Expert Review of Anticancer Therapy|November 28, 2023
Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trialsStefano Molica, David AllsupEuropean Journal of Haematology|March 12, 2026
Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) CareStefano Molica, David AllsupHematological Oncology|April 29, 2025
Fixed Duration Ibrutinib-Venetoclax, a Redefinition of the CLL Treatment LandscapeStefano Molica, David AllsupMediterranean Journal of Hematology and Infectious Diseases|July 10, 2025
Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical ViewStefano Molica, David AllsupHematological Oncology|March 19, 2022
Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemiaStefano Molica, Constantine Tam, Aaron PolliackCurrent Hematologic Malignancy Reports|June 6, 2020
The Evolution of Targeted Therapies in Chronic Lymphocytic LeukaemiaValentina Gianfelici, Luciano Levato, Stefano MolicaBMC Medicine|June 3, 2017
Spotlight on landmark oncology trials: the latest evidence and novel trial designsHelena Earl, Stefano Molica, Piotr RutkowskiActa Haematologica|August 7, 2023
Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management WorldwideStefano Molica, Marco Rossi, David AllsupFrontiers in Oncology|April 24, 2023
An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapiesSujoy Khan, David Allsup, Stefano MolicaExpert Opinion on Emerging Drugs|January 31, 2020
Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinibStefano Molica, Valentina Gianfelici, Luciano LevatoPageof 16